Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Payal Kapur, Christos Kyriakopoulos, Elaine T. Lam, Primo N. LaraClayton Lau, Bryan Lewis, David C. Madoff, Brandon Manley, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey Sosman, Mary A. Dwyer, Lisa A. Gurski, Angela Motter

Research output: Contribution to journalReview articlepeer-review

Abstract

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is important in therapy selection. The NCCN Guidelines for Kidney Cancer stratify treatment recommendations by histology recommendations for first-line treatment of ccRCC are also stratified by risk group. To further guidemanagement of advanced RCC, the NCCN Kidney Cancer Panel has categorized all systemic kidney cancer therapy regimens as "Preferred," "Other Recommended Regimens," or "Useful in Certain Circumstances." This categorization provides guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include pre-existing comorbidities, nature of the disease, and in some cases consideration of access to agents. This article summarizes surgical and systemic therapy recommendations for patients with relapsed or stage IV RCC.

Original languageEnglish (US)
Pages (from-to)71-90
Number of pages20
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume20
Issue number1
DOIs
StatePublished - Jan 2022

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology'. Together they form a unique fingerprint.

Cite this